**Supplementary Table 3.** Efficacy of the immunization with different doses of the attenuated L1-130 *fcpA*- mutant in mice followed by challenge with 108 leptospires of heterologous strain by intraperitoneal route

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine£** | **Challenge** | | **VaccineDose£** | **Expt.\*** | **Median days for death (range)** | | **% Vaccine protection** | | | | **% Vaccine Efficacy overall (95% CI)¶** | |
| **Death (No. survivors/total)** | | **Colonization  (No. negative/total)** | |
| **Species** | **Serovar/Strain** | **Vaccine** | **PBS**  **control** | **Vaccine** | **PBS**  **control** | **Vaccine** | **PBS**  **control** | **Death** | **Colonization** |
| *fcpA-* | *L. interrogans* | Manilae L495 | 107 | 1 | - | 3 (3-6) | 100 (8/8) | - (0/8) | 100 (8/8) | - (0/8) | 100  (82.4–100) | 100  (82.4-100) |
| 2 | - | 3 (3) | 100 (6/6) | - (0/6) | 100 (6/6) | - (0/6) |
| 3 | - | 3 (3-4) | 100 (4/4) | - (0/4) | 100 (4/4) | - (0/4) |
| 105 | 2 | - | 3 (3) | 100 (4/4) | - (0/4) | 50 (2/4) | - (0/4) | 100  (67.6–100) | 50  (21.5-78.5) |
| 3 | - | 3 (3-4) | 100 (4/4) | - (0/4) | 50 (2/4) | - (0/4) |
| 103 | 2 | - | 3 (3) | 100 (4/4) | - (0/4) | 25 (1/4) | - (0/4) | 100  (67.6-100) | 25  (7.1–59.1) |
| 3 | - | 3 (3-4) | 100 (4/4) | - (0/4) | 25 (1/4) | - (0/4) |
| 102 | 2 | 3.5 (3-4) | 3 (3) | 50 (2/4) | - (0/4) | 0 (0/4) | - (0/4) | 50  (21.5-78.5) | 0  (0-32.4) |
| 3 | 3.5 (3-4) | 3 (3-4) | 50 (2/4) | - (0/4) | 0 (0/4) | - (0/4) |
| 101 | 2 | 3.5 (3-4) | 3 (3) | 0 (0/4) | - (0/4) | 0 (0/4) | - (0/4) | 0  (0-32.4) | 0  (0-32.4) |
| 3 | 4 (3-5) | 3 (3-4) | 0 (0/4) | - (0/4) | 0 (0/4) | - (0/4) |

£ *Leptospira interrogans* serovar Copenhageni strain Fiocruz L1-130

\* The experiment identification refers to the group of strains that were tested at the same time

**¶** Calculations based on frequency of outcomes compared to PBS-immunized animals